INDIAN PHARMACOPOEIA COMMISSION



National Coordination Centre- Pharmacovigilance Programme of India (PvPI)

MINISTRY OF HEALTH & FAMILY WELFARE, GOVERNMENT OF INDIA

SECTOR-23, RAJ NAGAR, GHAZIABAD- 201 002.

Tel No: 0120-2783392, 2783400, 2783401, Fax: 0120-2783311 e-mail: pvpi.ipc@gov.in, ipclab@vsnl.net, Web: www.ipc.gov.in

File No. IPC/NCC-PvPI/DSA/2016-17/08

December 2016

Drug Safety Alerts

The preliminary analysis of SUSARs from the PvPI database reveals that the following drugs are associated with the risks as given below.

Table

Sl.No	Suspected Drugs	Indication	Adverse Reactions
1	Cefixime	Otitis media, respiratory tract infections, uncomplicated UTIs, effective against infections caused by Enterobaceriaceae, H.influenza species.	Anal Ulcer
2	Atenolol	Angina and myocardial infarction; arrhythmias; hypertension; migraine prophylaxis	Dermatitis Lichenoid
3	Olanzapine	Schizophrenia and other psychotic disorders, mania/mixed episode, psychomotor agitation and violent behaviour	Drug reaction with eosinophilia and systemic symptoms (DRESS syndrome)
4	Meropenem	Nosocomial infections like septicaemia, febrile neutropenia, intraabdominal and pelvic infection etc., caused by cephalosporin's resistant bacteria, meningitis cystic fibrosis	Hypokalaemia
5	Montelukast	Prophylaxis of mild to moderate asthma	Tinnitus

Health care professionals, Patients/Consumers are advised to closely monitor the possibility of the above adverse events associated with the use of above drugs. If such events are encountered please report to the NCC-PvPI either by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (http://www.ipc.gov.in) or by PvPI Helpline No. 1800-180-3024.